Collaborative Arrangements (Tables)

3 Months Ended

Mar. 31, 2019

Summarized information related to this collaboration is as follows:



	Three Months Ended March 31,
($ in millions)	2019		2018
Alliance revenue	$	79	$	33

Cost of sales⁽¹⁾	19		12
Selling, general and administrative	27		7
Research and development	45		29

($ in millions)	March 31, 2019		December 31, 2018
Receivables from AstraZeneca included in Other current assets	$	80	$	52
Payables to AstraZeneca included in Accrued and other current liabilities⁽²⁾	584		405
Payables to AstraZeneca included in Other Noncurrent Liabilities⁽²⁾	—		250

⁽¹⁾Represents amortization of capitalized milestone payments.

⁽²⁾Includes accrued milestone and license option payments.

Summarized information related to this collaboration is as follows:



	Three Months Ended March 31,
($ in millions)	2019		2018
Net product sales recorded by Merck	$	48	$	43
Merck’s profit share from sales in Bayer’s marketing territories	42		25
Total sales	90		68

Cost of sales⁽¹⁾	29		27
Selling, general and administrative	8		8
Research and development	30		28

($ in millions)	March 31, 2019		December 31, 2018
Receivables from Bayer included in Other current assets	$	33	$	32
Payables to Bayer included in Other Noncurrent Liabilities ⁽²⁾	375		375

⁽¹⁾Includes amortization of intangible assets.

⁽²⁾Includes accrued milestone payments.

Summarized information related to this collaboration is as follows:



	Three Months Ended March 31,
($ in millions)	2019		2018
Alliance revenue	$	74	$	—

Cost of sales⁽¹⁾	51		—
Selling, general and administrative	19		—
Research and development ⁽²⁾	47		1,400

($ in millions)	March 31, 2019		December 31, 2018
Receivables from Eisai included in Other current assets	$	75	$	71
Payables to Eisai included in Accrued and other current liabilities ⁽³⁾	557		375
Payables to Eisai included in Other Noncurrent Liabilities ⁽³⁾	325		543

⁽¹⁾Represents amortization of capitalized milestone payments.

⁽²⁾Amount in 2018 reflects the upfront payment and future option payments.

⁽³⁾Includes accrued milestone and option payments.